Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Greco F. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Cancer Invest 2013;
31:323-9. [PMID:
23614653 DOI:
10.3109/07357907.2013.789900]
[Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE
To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC).
METHODS
Patients with advanced RCC and ≤ 1 previous targeted therapy were treated.
RESULTS
Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common.
CONCLUSIONS
Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.
Collapse